Trial Profile
Multiple-Dose Pharmacokinetics of BMS-650032 in Subjects With Hepatic Impairment Compared to Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2019
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Ketoconazole
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 08 Mar 2011 Planned end date changed from 1 Mar 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
- 24 Jan 2011 Planned end date changed from Feb 2011 to Mar 2011 as reported by ClinicalTrials.gov.
- 06 Jan 2011 Planned end date changed from 1 Jan 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.